PharmaResearch - Public Comps and Valuation Multiples

PharmaResearch Overview

About PharmaResearch

PharmaResearch Co Ltd formerly Pharma Research Products Co Ltd is a bio pharmaceutical firm which realizes a new treatment paradigm for regenerative medicine. Its products include Rejuran, Rejuvenex, and Re-An eye drops. It also provides medical devices, cosme ceuticals, and dietary supplements.

Founded

2001

HQ

Employees

n/a

Website

pr-products.co.kr

Sectors

Regenerative Medicine
Medical Devices
Nutraceuticals & Cosmeceuticals
BioTech
DeepTech
HealthTech

Financials

LTM Revenue $376M

LTM EBITDA $165M

EV

$2.2B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

PharmaResearch Financials

As of February 2026, PharmaResearch reported last 12-month revenue of $376M and EBITDA of $165M.

In the same period, PharmaResearch generated $290M in LTM gross profit and $126M in net income.

See PharmaResearch valuation multiples based on analyst estimates

PharmaResearch P&L

In the most recent fiscal year, PharmaResearch reported revenue of $241M and EBITDA of $92.2M.

PharmaResearch expects next 12-month revenue of XXX and NTM EBITDA of XXX

See PharmaResearch valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$376M	XXX	$241M	XXX	XXX	XXX
Gross Profit	$290M	XXX	$173M	XXX	XXX	XXX
Gross Margin	77%	XXX	72%	XXX	XXX	XXX
EBITDA	$165M	XXX	$92.2M	XXX	XXX	XXX
EBITDA Margin	44%	XXX	38%	XXX	XXX	XXX
EBIT	$155M	XXX	$86.7M	XXX	XXX	XXX
EBIT Margin	41%	XXX	36%	XXX	XXX	XXX
Net Profit	$126M	XXX	$63.3M	XXX	XXX	XXX
Net Margin	33%	XXX	26%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for PharmaResearch including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $376M. EBITDA for the last twelve months was $165M. In the most recent fiscal year, PharmaResearch achieved $241M in revenue and $92.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$376M	Analyst estimates available to subscribers	$241M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$290M	Analyst estimates available to subscribers	$173M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	77.1% gross margin	Analyst estimates available to subscribers	71.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$165M	Analyst estimates available to subscribers	$92.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	43.8% EBITDA margin	Analyst estimates available to subscribers	38.3% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$155M	Analyst estimates available to subscribers	$86.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	41.2% EBIT margin	Analyst estimates available to subscribers	36.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$126M	Analyst estimates available to subscribers	$63.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	33.4% net profit margin	Analyst estimates available to subscribers	26.3% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for PharmaResearch

This financial data table provides comprehensive performance metrics for PharmaResearch, a company based in South Korea. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

PharmaResearch generated $376M in revenue over the last twelve months.
The company achieved $165M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $290M.
Net income over the last twelve months reached $126M.

Fiscal Year Performance

In the most recent fiscal year, PharmaResearch reported $241M in total revenue.
Fiscal year EBITDA was $92.2M.
The company maintained a gross profit margin of 71.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 38.3%.
Net profit margin reached 26.3% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for PharmaResearch. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

PharmaResearch Stock Performance

PharmaResearch has current market cap of KRW 3.67T (or $2.5B), and EV of KRW 3.14T (or $2.2B).

Market Cap Evolution

PharmaResearch Stock Data

As of March 4, 2026, PharmaResearch's stock price is KRW 353000 (or $243).

See PharmaResearch trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.2B	$2.5B	XXX	XXX	XXX	XXX	$11.46

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

PharmaResearch Valuation Multiples

PharmaResearch's trades at 5.7x EV/Revenue multiple, and 13.1x EV/EBITDA.

See valuation multiples for PharmaResearch and 15K+ public comps

PharmaResearch Financial Valuation Multiples

As of March 4, 2026, PharmaResearch has market cap of $2.5B and EV of $2.2B.

Equity research analysts estimate PharmaResearch's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

PharmaResearch has a P/E ratio of 20.1x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$2.5B	XXX	$2.5B	XXX	XXX	XXX
EV (current)	$2.2B	XXX	$2.2B	XXX	XXX	XXX
EV/Revenue	5.7x	XXX	5.7x	XXX	XXX	XXX
EV/EBITDA	13.1x	XXX	13.1x	XXX	XXX	XXX
EV/EBIT	13.9x	XXX	13.9x	XXX	XXX	XXX
EV/Gross Profit	7.4x	XXX	n/a	XXX	XXX	XXX
P/E	20.1x	XXX	20.1x	XXX	XXX	XXX
EV/FCF	21.3x	XXX	21.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get PharmaResearch Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

PharmaResearch Margins & Growth Rates

PharmaResearch's last 12 month revenue growth is 31%

PharmaResearch's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

PharmaResearch's rule of 40 is 75% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PharmaResearch's rule of X is 121% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for PharmaResearch and other 15K+ public comps

PharmaResearch Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	31%	XXX	27%	XXX	XXX	XXX
EBITDA Margin	44%	XXX	44%	XXX	XXX	XXX
EBITDA Growth	34%	XXX	44%	XXX	XXX	XXX
Rule of 40	75%	XXX	75%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	121%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	13%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	36%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial